Trials for GIST Cancer

Current clinical trials for GIST (gastrointestinal stromal tumor) are linkable entries in the list below.

Maps of Trial Locations

When you click this link you will see a world map of GIST cancer trials at the website.  In countries where there are trials you will see a small white block with a black number indicating how many trials are open there.  Click the black number to zoom in on the geographic area of your choice.  For example, if you click on the USA or Europe, another map will open showing trials in each state or country.  Click again on the state or country of your choice to see which trials are available there.  NOTE that some trials listed in the table below will NOT appear on this map if GIST is not specifically listed in the trial protocol; for example, trials for any solid tumor may not appear.

Trials by Drug Target

Clinical trials for GIST cancer are listed below according to the class of drug being tested (the target of the drug).  For each drug listed under each category, click “Trials at” to see the open trials relevant to GIST patients at the website

NOTE:  Drugs that are already FDA-approved for other cancers may be prescribed at the discretion of a physician outside of a clinical trial.  These drugs are indicated in the list below by “brand name” following the chemical name.

Tyrosine Kinase Inhibitors of KIT and/or PDGFRA:

Sunitinib:  Trials at

Regorafenib:  Trials at

Crenolanib  (CP-868,596): Trials at

PLX9486, PLX3397:  Trial at

DCC-2618:  Trials at

HSP90 Inhibitors:

AUY922Trials at

Inhibitors of Pathways Downstream of KIT /PDFRa and mTOR inhibitors:

Temsirolimus (brand name Torisel):  Trials at

Glutaminase inhibitors:

CB-839:  Trials at

Clinical trials for GIST

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST),  click here to view link on clinical

Phase Ib Study of Sunitinib Alternating With Regorafenib in Patients With Metastatic and/or Unresectable GIST (SURE), click here to view link in clinical

Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation, click here to view trial in clinical

Regorafenib Post-marketing Surveillance in Japan, click here to view trial in

The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib (REGORA), click here to view in

Stivarga Regulatory Post-Marketing Surveillance Study in Korea (StivargaPMS), click here to view in

PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors,  click here to view in

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST,  click here to view in

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies,  click here to view in

A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients,  click here to view in

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] (STAR-TOR),  click here to view link in

Clinical trials for Wildtype GIST

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRY),  click here to view link in

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors,  click here to view in

Clinical trials for Paragangliomas

131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma,  click here to view link on

First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma(FIRSTMAPPP),  click here to view in


This page is always under revision, and more trials will be added as they are identified.